Intra-Biotech Consolidation in Europe? Not Affordable.

Bankers and consultants have long been urging the virtues of consolidation onto a financially strapped biotech industry. But few companies on either side of the Atlantic have been listening.

Tracking intra-European dealmaking by type of acquirer and target, Windhover's Strategic Transactions Database shows that overall dealmaking has declined, with...